Roche — surprise — delays $4.3B Spark buyout again as regulators hover
Roche has yet again delayed their Spark buyout.
The Swiss giant extended the window on the $4.3 billion gene therapy acquisition through November 25th. It is delay #8 for a deal first announced in February.
Roche said the delay was to give UK and US regulators more time to review the acquisition. The Federal Trade Commission staff reviewing the deal reportedly recommended approval last week, months after a rare second information request some analysts thought could augur a divestiture demand. But a recommendation is not an official approval, and across the Atlantic, UK Competition and Markets Authority is not due to announce its Phase I decision until December 16.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.